A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Automated Counterflow Centrifugal System for Small-Scale Cell Processing

8.8K views

⸱

DOI:

10.3791/60423

⸱

December 12th, 2019

 ,  ,  ,  ,  ,  ,  ,  , 

In This Article

Summary

Automation is key to upscaling and cost management in cell manufacturing. This manuscript describes the use of a counterflow centrifugal cell processing device for automating the buffer exchange and cell concentration steps for small-scale bioprocessing.

Abstract

Successful commercialization of gene and cell-based therapies requires manufacturing processes that are cost-effective and scalable. Buffer exchange and product concentration are essential components for most manufacturing processes. However, at the early stages of product development, these steps are often performed manually. Manual dead-end centrifugation for buffer exchange is labor-intensive, costly, and not scalable. A closed automated system can effectively eliminate this laborious step, but implementation can be challenging. Here, we describe a newly developed cell processing device that is suitable for small- to medium-scale cell processing and aims to bridge the gap between manual processing and large-scale automation. This protocol can be easily applied to various cell types and processes by modifying the flow rate and centrifugation speed. Our protocol demonstrated high cell recovery with shorter processing times in comparison to the manual process. Cells recovered from the automated process also maintained their proliferation rates. The device can be applied as a modular component in a closed manufacturing process to accommodate steps such as buffer exchange, cell formulation, and cryopreservation.

Introduction

The landscape of modern medicine has transformed rapidly through recent developments in gene and cell-based therapies (GCT). As one of the fastest growing fields in translational research, the GCT sector also faces unique and unprecedented challenges. In addition to robust clinical outcomes, efficient and cost-effective manufacturing processes are essential for the commercial success of GCT, which is particularly difficult to achieve in small-scale manufacturing1. The cost of time, labor, and quality assurances are magnified when each batch of cells only produces a few doses for one patient instead of hundreds or thousands. Unlike allogeneic ce....

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Preparation of reagents and cells for buffer exchange

  1. Prepare buffers (see Table of Materials) in a class 2 laminar flow hood. Using a syringe and needle assembly, remove 50 mL of saline solution from a 500 mL saline bag. Replace this with 50 mL of 20% human serum albumin (HSA) to make 2% HSA in saline, which will serve as the wash buffer.
  2. Remove the cells from the culture vessels and perform a cell count to determine the starting cell quantity and viability by trypan blue exclusion. Load the cells into a transfer bag.
    NOTE: In this protocol Jurkat cells were cultured in RPMI and MSCs were cultured in DMEM:F12. Both med....

Access restricted. Please log in or start a trial to view this content.

Results

In this protocol, we used Jurkat cells and MSCs as representative examples to demonstrate the automated buffer exchange process. During the process, Jurkat cells and MSCs shared the same processing steps with differences in centrifugal force and pump speed that control the flow rate (Table 1). Figure 2 shows representative images captured by the camera of how the fluidized cell bed may appear during the buffer exchange process. Typically, the fluidized cell bed will resemble.......

Access restricted. Please log in or start a trial to view this content.

Discussion

The automated buffer exchange protocol described is simple and user friendly. Nevertheless, there are a few key steps in this protocol that are critical and require particular attention. In our experience, when processing larger cells such as MSCs (average diameter 10–15 µm) each run should include at least 1 x 107 cells to achieve optimal cell recovery (Figure 4B). Processing smaller cells, such as Jurkat cells (average ~10 µm diameter), requires .......

Access restricted. Please log in or start a trial to view this content.

Disclosures

SW, IF, and DJ are COO, CTO, and CEO of Scinogy Pty. Ltd. The access to the CFC device was also provided by Scinogy.

Acknowledgements

This work is supported by the Victorian Government's Operational Infrastructure Support Program, and the Victorian Government Technology Voucher provided by the Department of Economic Development, Jobs, Transport and Resources. RL is the recipient of a National Health and Medical Research Council Career Development Fellowship. AL is the recipient of an Australian Postgraduate Award.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
20 ml Luer lock syringesBD302830
20% Human serum albumin (HSA)CSL BehringAUST R 46283
4-(Dimethylamino)benzaldehydeSigma-Aldrich156477-25g
500ml IV saline bagFresenius KabiK690521
Antibiotic-AntimycoticThermo Fisher Scientific15240112
Automated cell counter (Countess)Thermo Fisher ScientificN/A
Cell counting chamber slidesThermo Fisher ScientificC10228
Cell stimulation cocktail (500x)Thermo Fisher Scientific00-4970-93
Cell transfer bagsTerumoT1BBT060CBB
CellTiter AQueous One Solution Cell Proliferation Assay (MTS)PromegaG3582
CentrifugeEppendorf5810R
DMEM: F12 mediaThermo Fisher Scientific11320082
EnVision plate ReaderPerkin ElmerN/A
Fetal bovine serum (FBS)Thermo Fisher Scientific10099141
Human Interleukin 2 (IL2) KitPerkin ElmerAl221C
Luer (female) fittingsCPCLF41
PC laptop or PC tablet deviceASUSN/A
Plate reader (SpectraMax i3)Molecular DeviceN/A
Recombinant Human IFN-γPeproTech300-02
Rotea counterflow centrifuge cell processing deviceScinogyN/A
Rotea single-use processing kitScinogyN/A
RPMI mediaThermo Fisher Scientific11875119
Surgical scissorsProSciTech420SS
Trichloroacetic acideSigma-AldrichT6399-250g
Trypan Blue stainThermo Fisher ScientificT10282
Trypsin digestion enzyme (TrypLE Express Enzyme)Thermo Fisher Scientific12604013

References

  1. Lopes, A. G., Sinclair, A., Frohlich, B. Cost Analysis of Cell Therapy Manufacture: Autologous Cell Therapies, Part 1. BioProcess International. 16 (3), (2018).
  2. Hampson, B., Ceccarelli, J. Factories of the future: Can Patient-Sp....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Counterflow CentrifugationAutomated Buffer ExchangeCell Processing DeviceSingle-Use Processing KitFluidized Cell BedHigh Cell RecoveryClosed Manufacturing SystemBuffer Exchange ProtocolCell Viability Assessment